SLNO
Soleno Therapeutics, Inc.
$52.95
+0.00%
2026-05-08
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Key Fundamentals
P/E Ratio
135.79
Forward P/E
-23.33
EPS (TTM)
$0.39
ROE
6.0%
Profit Margin
11.0%
Debt/Equity
11.68
Price/Book
6.15
Beta
-2.22
Market Cap
$2.76B
Avg Volume (10D)
1.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$52.96
60D Low
$29.47
Avg Volume
3.4M
Latest Close
$52.95
Get breakout alerts for SLNO
Sign up for Breakout Scanner to receive daily notifications when SLNO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Soleno Therapeutics, Inc. (SLNO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SLNO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SLNO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.